23:44 , Jun 19, 2019 |  BC Extra  |  Company News

Management tracks: Ultragenyx promotes Erik Harris to EVP, COO; plus F-star, Arbutus, Maze and more

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) promoted Erik Harris to EVP and chief commercial officer from SVP, head of North American commercial operations. Bispecific antibody company F-star Biotechnology Ltd . (Cambridge, U.K.) said CFO...
22:06 , May 7, 2019 |  BC Extra  |  Company News

May 7 Company Quick Takes: Akcea, Bicycle/DDF, Arbutus, Celgene/Sutro, MDGH, Pfizer, Sanofi/Regeneron

Akcea's Waylivra approved in EU  The European Commission granted conditional approval to Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as an adjunct to diet in adult patients with familial chylomicronemia...
01:20 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim...
23:44 , Nov 19, 2018 |  BC Extra  |  Company News

Management tracks: Brickell, Genevant

Dermatology company Brickell Biotech Inc. (Boulder, Colo.) hired Robert Brown as CEO, effective Jan. 1. He will replace co-founder and CEO Reginald Hardy, who will remain on the board and serve as special adviser to...
22:27 , Nov 1, 2018 |  BC Extra  |  Politics & Policy

FDA guides development of finite therapies to cure HBV

FDA released draft guidance Thursday to encourage development of finite, curative HBV treatments that have a low risk of virologic relapse and minimal risk of liver disease progression after treatment. FDA recommended developers use a...
17:59 , Oct 12, 2018 |  BC Week In Review  |  Company News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Oct. 9 after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market...
23:50 , Oct 9, 2018 |  BC Extra  |  Clinical News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Tuesday after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market cap....
17:35 , Sep 28, 2018 |  BC Week In Review  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Sept. 26, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400...
20:07 , Sep 26, 2018 |  BC Extra  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Wednesday, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400 million...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating hepatitis B surface antigen (HBsAg) levels in a broad population of patients with chronic HBV infection....